Myriad Genetics said it is in talks with UnitedHealthcare to ensure that enrollees continue to have access to its GeneSight mental health medication test after the insurer changed its coverage policy.

The genetic testing and precision medicine company on Monday said it strongly disagrees with UnitedHealthcare's inclusion of GeneSight after it announced it would no longer cover multi-panel genetic tests for behavioral-health diagnoses.

"Myriad is actively engaging with UnitedHealthcare to discuss the large body of evidence for Myriad's proprietary and clinically differentiated mental health medication test," the company said.

Myriad Genetics doesn't believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans, it added.

The company is expected to post third-quarter results after the market close Thursday.

Myriad Genetics shares were down 4.9% at $16.93 in morning trading. The stock has dropped 34% over the past three months.

Write to Sabela Ojea at [email protected]; @sabelaojeaguix